Navigation Links
Stopping unwanted cell death: Implications for drug discovery
Date:4/13/2008

BOSTON (April 13, 2008, 1:00 p.m. ET) Research published in Nature Chemical Biology reveals that three specific inhibitors of a cell death pathway, termed necroptosis, all target and inhibit RIP1 kinase, a protein that can direct cells into necrosis. Induced by trauma such as a heart attack or stroke, this form of necrotic death can result in tissue damage contributing to death or long-term disability. The findings present a novel avenue for drug development.

Our research found that RIP1 kinase can be inhibited by three small molecules: necrostatin-1, -3 and -5, reports first author Alexei Degterev, PhD, assistant professor at Tufts University School of Medicine and member of the biochemistry program faculty of the Sackler School of Graduate Biomedical Sciences. Overall, these data establish RIP1 kinase as a new target for therapeutic drug development for human diseases involving necrotic tissue injury, and they establish necrostatins as first-in-class potent and selective inhibitors of RIP1 kinase, the authors write, including last author, Junying Yuan, PhD, professor at Harvard Medical School.

Necrosis is relevant to many diseases, particularly those that involve an acute event, such as heart attack or stroke. Cells are programmed to die when they reach the end of their lifecycle and that regulated process is called apoptosis. Cells can also be killed through pathways not controlled by apoptosis. Until recently, this type of cell death, termed necrosis, was believed to be unregulated, a type of accidental cell death caused when cells are placed under extreme stress such as during a heart attack, stroke or organ failure, says Degterev.

Previous research, as well as research by others, determined that necroptosis, one type of necrosis, is regulated (like apoptosis) and has a specific biochemical pathway. Through our previous work, we have developed potent and specific small molecules capable of preventing necroptosis in isola
'/>"/>

Contact: Siobhan E. Gallagher
siobhan.gallagher@tufts.edu
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Steps toward Stopping Autoimmune Disease
2. From delicious to death: Understanding taste
3. Reflecting on the social implications of human genetics research -- past, present and future
4. Multiple species of bacteria may cause trachoma: Implications for treatment
5. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
6. Journey to the center of the earth: Discovery sheds light on mantle formation
7. UC San Diego researchers eliminate drug discovery bottleneck
8. Work with power grids leads to cell biology discovery
9. Surprising discovery from first large-scale analysis of biodiversity and biogeography of viruses
10. International team announces discovery of massive Jurassic marine reptile
11. Gene discovery made easier with powerful new networking technique
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stopping unwanted cell death: Implications for drug discovery
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... (NYSE: A) today announced that it has for the ... annotation information for all of its microarrays. The release ... research and cross-platform data comparison. , "Full release of ... for Agilent to take," said Catherine Ball, president of ...
... with huge 10 centimetre-long nails spoke volumes. But now definitive ... sighting of a grizzly bear. The discovery fuels mounting evidence ... of the polar bear -- Nanuk is having to make ... barren ground grizzly bear (Ursus arctos) was discovered on Melville ...
... growth of the earliest cities in northern China starting ... the result of successful rice farming combined with other ... Although we often associate rice with Chinese agriculture, most ... that was the most important food associated with northern ...
Cached Biology News:Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays 2Grizzlies set to invade high Arctic? 2
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015   Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... supply industries, today reported financial results for the second ... half of 2015, we remain on track to achieve ... and Chief Executive Officer of the Company. "Since our ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... July 30 Varian, Inc.,(NasdaqGS: VARI) announced today ... The TPS-compact provides plug-and-play, hydrocarbon free,ultra-high vacuum pumping ... a,light (max weight 19.1kg/42.1lbs.) scroll pump., The ... by,either the Turbo-V 81 MacroTorr(TM) or Turbo-V 301 ...
... July 30 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX:,MS), a ... today,announced that Mr. Kevin Giese, President and CEO, will ... in New York., WHEN: Wednesday August ... Broadway Hotel, New York About BioMS Medical Corp., ...
... , - Shares Acquired From Biggar Limited, ... company,focused on eye disease, vascular disease and cancer, ... in Belgium have together acquired an 8%,stake in ... Limited, a,charitable foundation that is ThromboGenics largest shareholder. ...
Cached Biology Technology:New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum. 2BioMS Medical to present at BMO Healthcare Conference 2ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 2ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 3
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: